CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This study to evaluate treatment in patients with metastatic renal cell carcinoma (RCC) which
has progressed through 2 to 3 prior lines of therapy, with the investigational drug CRLX101
in combination with bevacizumab compared to treatment with a standard of care therapy. The
study will compare which treatment resulted in longer time before progression of the RCC.
Patients will be treated and followed for progression of their disease on average for up to 6
months.